Currently, HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a major
component of the highly active anti-retroviral therapy (HAART) regimen. However, the …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) nowadays represent very potent
and most promising anti‐AIDS agents that specifically target the HIV‐1 reverse transcriptase …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most
promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT) …

Human immunodeficiency virus (HIV) is the primary infectious agent of acquired
immunodeficiency syndrome (AIDS), and non-nucleoside reverse transcriptase inhibitors …

The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse
transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations …

Currently, five NNRTIs have been approved by US Food and Drug Administration (US FDA)
for the clinical treatment of AIDS, ie, nevirapine, delavirdine, efavirenz, etravirine, and …

HIV-1 reverse transcriptase is one of the most attractive targets for the treatment of AIDS.
However, the rapid emergence of drug-resistant strains and unsatisfactory drug-like …

High-throughput screening hit 1 was identified as a potent, broad-spectrum, non-nucleoside
reverse transcriptase inhibitor (NNRTI) of HIV-1 replication. Analysis of the bound …

Currently, the long-term usage of non-nucleoside reverse transcriptase inhibitors (NNRTIs)
in HIV/AIDS patients eventually leads to the development of drug resistance and severe side …

The development of novel non-nucleoside inhibitors (NNRTIs) with activity against variants
of HIV reverse transcriptase (RT) is crucial for overcoming treatment failure. The NNRTIs …